MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, has announced that its Life Science business sector is investing more than $286 million in its biosafety testing capacity at the company’s site in Rockville, Maryland, USA.   This will significantly increase the company’s ability to conduct biosafety testing and analytical development services. Biosafety testing and analytical development are critical and fundamental requirements of the drug developmen...